BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 18c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.98), $0.18 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.99 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord
• SPAR Group (SGRP) Reports Q2 EPS of $0.04
• BridgeBio Pharma (BBIO) PT Raised to $115 at Piper Sandler as 'Attruby Outperforms'